ClinicalTrials.gov
public full text
Public Domain
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Adjuvant radiotherapy for WHO grade II meningiomas: the unanswered question.#354943
- Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer#866680
- Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma#979039
- Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma#812668
- Study of Dasatinib (BMS-354825) in Patients With Solid Tumors#907849
Record · ID 834625
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive